Results 111 to 120 of about 9,061 (176)

miR-640 Enhances Abemaciclib Sensitivity by Suppressing CDK Inhibitor Resistance-Associated Genes in Breast Cancer Cells. [PDF]

J Cell Mol Med
Alkac IM, Biray Avci C.
europepmc   +1 more source

TRADE: tolerability of adjuvant abemaciclib at 6 months after initial dose escalation in patients with early-stage HR-positive/HER2-negative breast cancer. [PDF]

ESMO Open
Schlam I, Trapani D, Kim SE, Heiling H, Faggen M, Sinclair N, Sanz-Altamira P, Battelli C, Berwick S, Lo S, Acevedo J, Sinclair S, Malcolm A, Varella L, Sammons S, Schumer S, Poorvu PD, Wallace E, Pasternak E, Tayob N, Tolaney SM, Mayer EL.   +21 more
europepmc   +1 more source

A Systematic Literature Review of the Effectiveness of CDK 4/6 Inhibitors for First-Line Treatment of HR+/HER2- Advanced/Metastatic Breast Cancer: A Comparison of Real-World Evidence. [PDF]

Cancers (Basel)
Pluard T, Grinda T, Dienstmann R, Thill M, Korytowsky B, Chen C, Portuhay S, Salvo-Halloran EM, Samjoo IA, Harbeck N.   +9 more
europepmc   +1 more source

Adjuvant CDK4/6 inhibitors in early-stage breast cancer: Clinical evidence and considerations for risk stratification and treatment selection. [PDF]

Cancer
Williams AD, Weiss A.
europepmc   +1 more source

Rb-driven transcription limits its tumour-suppressive effects in breast cancer. [PDF]

Nature
Watt AC, Ahn A, Blyth C, Dixon-Douglas JR, Ambani K, Coulson R, Taylor M, Chan KT, Dietrich C, Russ BE, Ramm S, Mahendra CA, Lu KH, Pires N, Garcia-Sannicolas J, Voulgaris O, Nunag S, Ang CS, Dawson MA, Lim E, Arnedos M, Chandarlapaty S, André F, Goel S.   +23 more
europepmc   +1 more source

Gastrointestinal toxicity associated with cyclin-dependent kinase 4/6 inhibitors in breast cancer patients: insights from a real-world pharmacovigilance analysis. [PDF]

Front Med (Lausanne)
Lu M, Yuan L, Liu J, Dou Y, Cui J.
europepmc   +1 more source

Real-world data on patients with HR+, HER2- early breast cancer prescribed with abemaciclib adjuvant therapy for 2 years in Japan. [PDF]

Future Oncol
Ozaki Y, Urano M, Sekine N, Lida M, Osaga S, Toshima G, Takemura R, Masuda N.   +7 more
europepmc   +1 more source

Comparative safety signal prioritization of CDK4/6 inhibitors in breast cancer: a FAERS pharmacovigilance, machine learning, and clinical contextualization study. [PDF]

Front Pharmacol
Fan L, Liu S, Tang Y, Han X, Zhang Z, Su C, Sui Z, Zhao W.   +7 more
europepmc   +1 more source

A process for the purification of Abemaciclib

The present publication relates to a process for the purification of Abemaciclib, chemically known as N-[5-[(4-ethyl-l-piperazinyl) methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1- (1-methylethyl)-1H-benzimidazol-6-yl]-2-pyrimidinamineof Formula ...
Anonymous
core  

<i>CDK4/6</i> Inhibitors in Breast Cancer: Clinical Applications, Translational Insights, and Future Directions. [PDF]

Cancers (Basel)
Guan M, Hao H.
europepmc   +1 more source